Harbor Capital Advisors, Inc. Moon Lake Immunotherapeutics Transaction History
Harbor Capital Advisors, Inc.
- $1.29 Billion
- Q3 2025
A detailed history of Harbor Capital Advisors, Inc. transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Harbor Capital Advisors, Inc. holds 13,706 shares of MLTX stock, worth $125,546. This represents 0.01% of its overall portfolio holdings.
Number of Shares
13,706
Previous 51,409
73.34%
Holding current value
$125,546
Previous $2.43 Million
95.96%
% of portfolio
0.01%
Previous 0.1%
Shares
7 transactions
Others Institutions Holding MLTX
# of Institutions
156Shares Held
54.5MCall Options Held
799KPut Options Held
661K-
Bvf Inc San Francisco, CA19.8MShares$181 Million36.63% of portfolio
-
Cormorant Asset Management, LP Boston, MA8.49MShares$77.8 Million40.43% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.15MShares$38 Million3.57% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.61MShares$23.9 Million0.01% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.67MShares$15.3 Million0.01% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $338M
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...